News from zafgen, inc

Feb 28, 2014, 07:00 ET

Zafgen Announces Support of NORD in Observing Rare Disease Day

Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced it will join...

Jan 15, 2014, 07:00 ET

Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome

 Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced initial...

Jan 09, 2014, 08:00 ET

Zafgen to Present at 32nd Annual J.P. Morgan Healthcare Conference

 Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced that...

Jan 09, 2014, 07:00 ET

Zafgen Appoints Chief Commercial Officer and New Member of Board of Directors

 Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced the...

Dec 04, 2013, 08:00 ET

Zafgen Secures $45 Million in Series E Financing

Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced it has...

Nov 15, 2013, 07:00 ET

Zafgen Announces New Weight Loss and Safety Data from Phase 2 Study of Beloranib in Obesity at Obesity Week 2013

 Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced final...

Jun 22, 2013, 11:00 ET

Zafgen Announces New Body Weight Loss and Cardiometabolic Data from Phase 2 Study of Beloranib in Obesity at American Diabetes Association's 73rd Scientific Sessions®

 Zafgen, Inc. today announced new data from an interim analysis conducted from an ongoing Phase 2 study of beloranib, a selective methionine...

Jan 04, 2013, 08:30 ET

Zafgen Appoints 20-Year Biotechnology Industry Veteran Patricia Allen, CPA, as Chief Financial Officer

 Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced the...

Dec 04, 2012, 08:00 ET

Zafgen Secures $21 Million in Series D Financing

 Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced it has...

Nov 06, 2012, 08:00 ET

Zafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity

Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced that it has...

Sep 22, 2012, 13:00 ET

Zafgen Announces Additional Weight Loss and Cardiometabolic Data from Phase 1b Studies of Beloranib in Obesity at Obesity 2012, the 30th Annual Scientific Meeting of The Obesity Society

 Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced new data...

Jun 10, 2012, 10:56 ET

Zafgen Announces Additional Weight Loss and Cardiometabolic Data from Phase 1 Studies of Beloranib in Obesity at American Diabetes Association's 72nd Scientific Sessions®

Zafgen, Inc., the world's first biopharmaceutical company dedicated to addressing the unmet need of severely obese patients, today announced new...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

ReportBuyer
Research and Markets
Investor-Edge